Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy
- Sponsor
- Centre Hospitalier Universitaire de Besancon
- Study ID
- NCT02843789
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tocilizumab — DRUG
Study Details
The aim of this study is to analyze the variation of adiponectinemia and its molecular forms in RA patients receiving tocilizumab therapy.
Key Dates
- Start date
- Mar 31, 2013
- Status verified
- Feb 2018
- Primary completion
- Nov 30, 2017
- Completion
- Nov 30, 2017
Study Design
- Enrollment
- 109 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Adiponectin evaluationPatients evaluated for serum adiponectin level and for body composition before each infusion of Tocilizumab
Primary Outcome Measure
Serum total adiponectin (ng/ml) [ Time Frame: 12 months ]
Related Studies
- Laser-based Photoacoustic Tomography of Human Inflammatory ArthritisRecruiting · University of Michigan · Ann Arbor, Michigan
- IMPACT - AndHealth Autoimmune Research RegistryRecruiting · AndHealth · Columbus, Ohio
- R-2487 in Patients With Rheumatoid ArthritisPHASE1 · Recruiting · Rise Therapeutics LLC · San Diego, California
- Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid ArthritisNot Yet Recruiting · Tufts Medical Center · Boston, Massachusetts